<DOC>
	<DOCNO>NCT00613197</DOCNO>
	<brief_summary>The primary objective study assess ability EpanovaTM Soft Gelatin Capsules total daily dose 4g ( 4x 1g capsule ) maintain remission ( Crohn 's Disease Activity Index CDAI &lt; 150 ) CD patient remission , stable least three month longer one year , induced corticosteroid , azathioprine/6-MP , methotrexate , 5-ASA antibiotic . Secondary objective ass : efficacy Epanova versus placebo Crohn 's Disease Activity Index ( CDAI ) , Investigator Subject Global Ratings , employment status use CD relate medical visit subject CD remission safety tolerability Epanova ability Epanova maintain quality life CD patient remission</brief_summary>
	<brief_title>EPANOVA Crohn 's Disease , Study 1</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Male female subject , age 17 old ; countryspecific age limitation follow 2 . Diagnosis Crohn 's disease confirm radiological study endoscopy surgical pathology within 36 month prior randomisation 3 . In remission least 3 month , longer 12 month ; remission define meet two condition : ( 1 ) clinically remission CDAI le 150 ( 2 ) steroid and/or immunosuppressant least 3 month , remission induce medication 1 . Intolerance omega3 fatty acid know allergy fish fish product 2 . Ongoing CD therapy : 5ASA compound , steroid , immune modifier , systemic antibiotic , tube feeding , define formula diet parenteral nutrition 3 . In 3 month prior randomisation receive : systemic steroid therapy , azathioprine , 6mercaptopurine , methotrexate , cyclosporine , probiotic product preparation contain fish oil 4 . In 12 month prior randomisation receive : biologicals e.g . enbrel , infliximab , mycophenolate , tacrolimus , thalidomide , immune modifier and/or investigational product 5 . Chronic use narcotic pain control ( opiates diarrhoea acceptable ) 6 . Documented short bowel syndrome , ostomy 7 . Need bowel surgery CD , bowel obstruction resection past 3 month ( subject bowel resection past must least one relapse surgery ) 8 . Malignancy and/or clinically significant impairment cardiac , liver renal function , CNS , pulmonary , hematological , immunological , vascular gastrointestinal disease addition CD 9 . Known alcoholism drug abuse 10 . Any medical condition , investigator 's opinion , may interfere evaluation trial medication 11 . Any following laboratory abnormality : White blood count &lt; 3 x 109/L Lymphocyte count &lt; 0.5 x 109/L Haemoglobin &lt; 80 g/L Platelet count &lt; 125 x 109/L &gt; 800 x 109/L ALT AST &gt; 2.0 time upper limit normal Alkaline Phosphatase &gt; 2.0 time upper limit normal Serum Creatinine &gt; 1.5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>